Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

What If We’ve Missed the Beauty of Sex? | The Gospels | Matthew 5:27–32 16 min · 25 Sep 2026 · Ten Minute Bible Talks Devotional Bible Study

Trump’s Standoff With White House Reporters, and the Rise and Fall of ‘Pervert Glasses’ 14 min · 25 Sep 2026 · The Headlines

Green Demon - Classic 34 min · 25 Sep 2026 · Spooked

Trump Unleashes Secret Biblical Strategy Against Xi Jinping 22 min · 25 Sep 2026 · Politics By Faith w/Mike Slater

Big meet, little meat: the Trump-Xi summit 27 min · 25 Sep 2026 · Economist Podcasts

Report any issue

Source

Recorded08 Sep 2026

Publisheraudiomedica.com ↗

Handlerec:20291147

Show notes

CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in